WASHINGTON DC—Laboratory evidence that giving patients intermittent rather than continuous treatment with cancer drugs could help them overcome drug resistance in cancers such as melanoma was presented at the American Association for Cancer Research 2013 meeting. Dr Darrin Stuart from the Novartis Institutes for Biomedical Research in Emeryville, California, presented research findings on mice treated with vemurafenib. He told Peter Goodwin why he thought this should prompt clinicians to look carefully at drug scheduling and consider intermittent therapy as a means of overcoming resistance in patients with cancer.
You may also like...
Pembrolizumab: No Survival Gains Second Line In Gastric Cancer 18 Oct, 2018 Audio Journal of Oncology Volume 16 Number 10 25 May, 2008 Enzalutamide in metastatic castration resistant prostate cancer: over 75s benefit too 24 Mar, 2013 ASCO Audio Journal of Oncology in Advance – June 15th, 2007 – reporting from: ASCO Annual Meeting, Chicago, June 1-5, 2007 16 Jun, 2007
- Previous story Blood test reliably detects cancer mutations in gastrointestinal stromal tumour
- Next story BRCA-deficient cancers respond to combination of two experimental drugs
- COVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014